Avance Clinical, a leading global CRO specializing in clinical
trials for the biotech sector, has won the prestigious 2024 Frost
& Sullivan Best Practices Customer Value Leadership Award for
Global Biotech CRO Excellence.
Avance Clinical CEO Yvonne Lungershausen thanked
Frost & Sullivan for the global award and said they recognized
the entire Avance Clinical team across the globe working together
to accelerate clients’ drug development.
“Our agile, customer centric and integrated
approach to progressing clinical research for our biotech clients
is clearly resonating in an industry that too often has a one size
fits all model,” she said.
Frost & Sullivan is a globally recognized
authority in identifying and honoring companies that demonstrate
excellence leadership, innovation and growth.
According to Frost & Sullivan, “These
companies consolidate their leadership positions by innovating and
creating new products, solutions, and services that meet
ever-evolving customer needs. By strategically broadening their
product portfolios, leading companies advance the overall market.
Driving innovation and growth is a difficult task made even harder
by the strategic imperatives forcing change today, such as
disruptive technologies, value chain compression, industry
convergence, and new business models”.
“In this context, Avance Clinical’s recognition
signifies an even greater accomplishment.”
The award report noted that Avance Clinical,
headquartered in Adelaide, Australia, is now a leading global CRO
facilitating top-tier clinical trials with globally recognized data
for biotech firms worldwide.
“With an exclusive focus on the biotech sector,
the company has significant deep clinical research experience
across 250+ therapeutic indications to provide customized services
catering to biotech R&D’s dynamic needs,” said the report.
The report also highlighted that Avance Clinical
has particularly robust expertise in Cell & Gene Therapies,
Central Nervous System (CNS), Dermatology, Endocrinology,
Infectious Diseases, Oncology, Ophthalmology, Rare Disease &
Orphan Drug, and Respiratory & Allergy indications. Overall,
the company’s world-class team exceeding 330 clinical and
regulatory specialists delivers high-quality clinical trials in
Australia, New Zealand, Asia, and North America for international
biotechs.
Frost & Sullivan also noted that: “The
company’s flat organizational structure provides customers with
direct access to leadership teams, facilitating continual
collaboration throughout their drug development journeys”.
The report said that the company’s unique
approach to project management, where each project receives
individual oversight, has resulted in high customer satisfaction
rates and impressive client retention.
Frost & Sullivan said Avance Clinical
offered a strong business case for biotechs. Especially considering
their research “found over 50% of biotechs engage with more than
one CRO throughout their clinical programs, leading to a less
streamlined approach that increases project costs, delays, and
knowledge/data transfer challenges”.
“Unlike larger multinational CROs, this intimate
approach enables Avance Clinical to understand customer challenges
closely, empowering it to deliver flexible solutions and hands-on
guidance that optimally position it to match the fast-paced nature
of biotech R&D. As a result, the company’s agility and
responsiveness make it the ideal partner for small to mid-sized
biotech companies, addressing a crucial need that competitors often
struggle to fulfill,” said Unmesh Lal, Global Research
Director.
The award report also noted:
- In-House Regulatory
Affairs: One of Avance Clinical’s most compelling value
propositions is its in-house regulatory team that seamlessly
integrates into its biotech clients’ clinical and project delivery
operations to minimize delays and costly errors (decreasing the
trial startup timeline by up to 50% and reducing costs by up to
30%).
- Site Partnerships:
Avance Clinical continues to invest strategically in building
strong relationships with clinical sites capable of conducting
Phase I to IV clinical trials, forming an expansive network of over
2,000 high-quality, trusted clinical trial sites across Australia,
New Zealand, the US, Canada, and Europe.
- Advanced
Technology: In addition to facilitating a company-wide
application of industry-standard technologies, Avance Clinical’s
Technology and Innovations team continually identifies and reviews
the latest technology solutions, including machine learning and
artificial intelligence (AI) applications, to support global
systems integrations.
- A Global Approach:
The company’s unique GlobalReady model supports biotechs from their
early pre-clinical stage through to later phases across the globe,
leveraging the right site relationships to deliver access to the
optimal patient populations. The GlobalReady program enables
seamless transition and coordination between regions, allowing
biotechs to utilize its expertise across various markets.
- Expedited
Recruitment: Avance Clinical’s strong network facilitates
quick feasibility evaluations and rapid progression through
start-up activities, allowing for expedited patient recruitment.
This efficiency, in turn, translates to shorter overall timelines
for the company’s biotech clients, ensuring faster and more
effective clinical trials, including accelerated study start-up
durations of five to six weeks.
Sama Suwal, the Best Practice Research Analyst at Frost &
Sullivan said Avance Clinical’s global network is a clear advantage
for its clients, “Avance Clinical’s globalized strategy extends its
presence into new geographies through organic expansions and
partnerships to better serve its biotech customers’ growing global
needs…the company continues to spread its footprint across the
United States (US) and Asia while strengthening its CRO
partnerships through Europe”.
Find out more:• Learn
about the GlobalReady model• For more
information about the benefits of running your next study with
Avance Clinical contact us• Request a
Proposal here
About Avance Clinical
| Request a ProposalAvance
Clinical is the largest premium full-service Australian, Asian and
North American CRO delivering quality clinical trials with globally
accepted data for international biotechs. The company’s clients are
biotechs completing Phase I to Phase III of their drug development
program that requires fast, agile, and adaptive solution-oriented
clinical research services.
Frost & Sullivan AwardsAvance Clinical, a
Frost & Sullivan Asia-Pacific CRO Market Leadership Award
recipient for the past four years, has been providing CRO services
in the region for more than three decades.
Pre-clinical through to mid to late phaseAvance
Clinical offers pre-clinical consulting and regulatory services
with their experienced ClinicReady team right from pre-clinical
consultancy through to Phase III clinical services leveraging
significant Australian Government incentive rebates of up to 43.5%
and rapid start-up regulatory processes.
With experience across more than 250 indications, the CRO can
deliver world-class results and high-quality internationally
accepted data for TGA, FDA and EMA review.
TechnologyAvance Clinical uses state-of-the-art
technology and gold standard systems across all functional areas to
provide clients with the most effective processes. Medidata,
Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just
some of the technology partners.www.avancecro.com
Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson